inmun inc inmb buy pt mobil arm immun innat respons initi coverag
buy rate pt analyst jason mccarthi ph full summari
livexl media inc buy pt expect strong growth live music stream initi coverag
buy rate price analyst allen klee cfa full summari
inc buy pt maintain buy rais pt momentum oliv
garden longhorn potenti cheddar turnaround analyst stephen anderson full summari
virtra inc vtsi buy pt preview shave estim lower growth assumpt maintain buy pt
long-term initi analyst allen klee cfa full summari
azurrx biopharma inc azrx buy pt phase data chronic pancreat present digest diseas
week may analyst carolin palomequ full summari
bionano genom inc bngo buy pt updat saphyr revenu grow awar build financ
activ posit analyst jason mccarthi ph full summari
corpor event call maxim salesperson inform
intern inc tpnl cover diana ndr nyc evp strateg develop jim mccroy tue
reneuron group plc rene cover mccarthi ndr nyc ceo olav hellebo cfo michael hunt
stealthga inc gass cover jang ndr nyc ceo harri vafia tue
genco ship trade ltd cover jang ndr chicago ceo john wobensmith cfo
navig hold ltd nvg cover jang group luncheon new york ceo david butter wed apr
pm et
tuanch limit tc cover jang ndr toronto cfo troy mao investor relat dana cheng mon
tuanch limit tc cover jang ndr nyc cfo troy mao investor relat dana cheng wed
tuanch limit tc cover jang ndr boston cfo troy mao investor relat dana cheng thu
tuanch limit tc cover jang ndr chicago cfo troy mao investor relat dana cheng
tuanch limit tc cover jang ndr dalla cfo troy mao investor relat dana cheng wed
tuanch limit tc cover jang ndr san francisco cfo troy mao investor relat dana cheng
tuanch limit tc cover jang ndr lo angel cfo troy mao investor relat dana cheng
cover jang ndr boston ceo gari vogel cfo frank decostanzo
director strategi busi develop costa tsoutsoplid tue apr
maxim group industri confer nyc mygr host sullivan thu
corpor cover ndr milwauke evp cao cfo mark wolfing
svp financ robert verostek tue may
cover klee ndr chicago presid ceo michael prior cfo
turtl beach corpor hear cover chokshi ndr dalla ceo juergen stark thur
cover klee ndr milwauke presid ceo michael prior cfo
inc cover klee ndr nyc ceo steve picket cfo ahlstrom tue apr
inc cover klee ndr boston ceo steve picket cfo ahlstrom wed apr
inc cover klee ndr chicago ceo steve picket cfo ahlstrom thu apr
annual silicon valley bu tour host chokshi tue jul
expect strong growth live music stream
initi coverag buy rate price target
livexl media take earli lead attract live music market
plan stream festiv event follow year
play stream music fastest grow area music
grow content livexl websit slacker radio
key subscript revenu growth driver partnership
nr get monthli payment everi vehicl deliv
manag like introduc guidanc may sell-sid
estim seem aggress revenu forecast million compar
consensu howev forecast repres growth
base manag vision analysi dcf-base price target
includ revenu grow next five year
reach subscrib vs festiv vs
note live music festiv per year grow
initi buy rate price target base dcf analysi
equat revenu estim
livexl pure play music stream live music market live music
event repres larg market posit grow number event
produc multipl partnership particip music stream fastest
grow segment music consumpt track stream event
goal five year compani gener
revenu advertis sponsorship distribut content oper
livexl websit app download across multipl connect devic
expand channel offer type music avail develop
content develop espn like experi compani own slacker
radio internet radio servic free subscript plan subscript
revenu account revenu anoth key revenu sourc compani
agreement auto telecom carrier emb slacker servic
current revenu provid everi north american car deliv
make per month per car
earli stage hypergrowth growth driver increas
subscrib festival/ev stream increas viewership
relat advertis sponsor distribut relat revenu project revenu
increas y/i y/i
potenti go next year base compani five-
year goal reach subscrib stream event year model
given earli stage growth plan project neg free cash flow
turn posit result compani like
need rais capit order continu execut growth plan
initi coverag buy rate price target price target base
discount cash flow analysi dcf use wacc termin
growth rate termin multipl valu trade revenu
estim price target equat revenu estim peer group
trade revenu estim rate reflect posit view live
music stream over-the-top market compani larg market
opportun manag histor track record industri experi note
insid stock
click full note
mobil arm immun innat respons
 initi coverag buy rate pt
initi coverag inmun buy rate price
target inmun clinical-stag immunotherapi compani three drug
program focus har innat immun system treat cancer
neurodegen diseas inkmun
select tnf inhibitor downregul immunosuppress
factor found tumor microenviron turn cold tumor hot
tnf select target solubl form tnf may inhibit activ
microglia type innat immun cell differenti approach vs target
beta amyloid tau preclin data posit initi
inkmun modifi tumor cell line prime exist natur killer nk
conclus innat immun space continu evolv rise
behind car-t checkpoint target adapt immun multipl
player space includ big pharma/biotech inmun program
report data provid catalyst stock support higher
adapt vs innat immun system bodi immun system must abl
distinguish individu cell vs harm invad tackl
immun system divid two compon innat adapt innat immun
immedi non-specif initi respons serv bodi first line defens
infect contrast adapt immun character highli specif
respons particular pathogen antigen develop prior exposur
tumor cell develop highli effect way escap immun surveil drug
develop immunotherapi date focus leverag adapt immun
system inmun bio therapeut inkmun aim har innat
immun system target biomarker-driven approach could potenti
offer clinic benefit cancer patient either monotherapi combin
turn cold tumor hot increas tnf signal alter immun
cell profil tumor microenviron tme turn shield tumor
attack patient immun system also call novel
dominant-neg tnf protein select neutral human solubl tnf stnf
inflammatori cytokin increas patient advanc cancer well
csf brain post-mortem patient certain neurodegen disord
alzheim diseas ad disrupt biolog activ stnf
select decreas activ transmembran receptor
spare transmembran tnf tmtnf thu maintain protect role
tnf differenti fda-approv first-gen anti-tnf biolog
humira enbrel other inhibit stnf tmtnf inmun
compet nr nr first gen non-
select tnf inhibitor develop inhibit mdsc tme drug may
improv respons checkpoint
valuat model solid tumor us eu au
inkmun r/r ovarian cancer us eu
alzheim diseas us eu au risk adjust factor
base stage develop clinic trial risk factor io
ad discount appli dep sop model equal
weight deriv price target
click full note
maintain buy rais pt momentum
oliv garden longhorn potenti cheddar
maintain buy rate rais price
target ahead releas februari result
thursday march open
increas ep vs consensu
base estim blend comp vs
consensu anticip strong result oliv garden ttm sale
longhorn ttm sale
rais ep estim vs consensu
ep estim vs consensu
ep estim vs consensu continu
expect comp out-performance peer well margin expans
model turnaround cheddar ttm sale expect
sale boost improv throughput addit online/mobil
despit recent discuss believ least year two away
make anoth acquisit
upwardli revis price target base updat sum-of-part
analysi base forecast
increas ep base estim
blend comp specif rais comp estim oliv garden
vs consensu comp estim longhorn
vs consensu also increas blend comp
estim dri higher-end brand vs consensu
rais ep estim ep estim
ep estim continu
expect comp out-performance peer well margin expans
expect least increas low end guidanc rang
rais guidanc rang outright strength result take
account fact fiscal year well slower ep growth
expect follow model low-teen percent ep compound-annual-growth-rate
valuat remain attract view share trade valuat
revis ep estim revis ep
estim multipl roughli line full-servic dine
averag dri long-run averag multipl argu dri above-
peer same-restaur sale driven growth in-restaur
traffic off-premis sale well margin expans strong free cash flow
gener warrant modest premium sector averag multipl
upwardli revis price target base updat sum-
of-part valuat weigh dri mass-market casual dine concept
higher-end fine dine upscal casual concept franchise/licens incom
use new prior valuat year price target also correspond
company-wid forward price-to-earnings ratio forward ev/ebitda ratio
compani post-r lobster spin-off averag ratio
moreov believ buyback dri million share repurchas
author well dividend yield provid opportun addit
click full note
preview shave estim lower growth
assumpt maintain buy pt long-term
project revenu y/i gross margin
ep break-even reduc previou estim
lower revenu adjust ep
reflect slower ramp new busi lower margin
maintain revenu y/i non-gaap ep
remain posit opportun expand domest polic
depart militari intern compani low
caution investor focu one quarter perform given
lumpi busi long sale cycl focu result
forward book help smooth shorter term
stock trade ep estim target base
ep estim use multipl line peer
believ virtra attract long-term growth polic depart
militari along intern confer call thursday
march et project revenu y/i compar
unusu weak prior year quarter project gross margin
expect modestli impact china tariff volum result project
non-gaap ep break-even reduc end
compani backlog gener book caution
investor focu overli quarterli result given lumpi busi
rather focu forward-look book result lower
revenu given lack announc new
larg win recent result non-gaap ep drop
revenu estim y/i factor repeat
unusu larg win occur expect compani
roll sever enhanc new product current develop
compani also announc recur revenu train offer expect
law enforc continu virtra largest end market believ
greater focu militari market note recent depart homeland
secur highlight superior virtra simul mention
potenti train tool maintain revenu y/i non-
gaap ep
virtra stand compar compani size profit
conserv balanc sheet attract growth outlook
expect growth come continu market share gain domest polic
depart militari intern polic depart municip
increas pressur provid best train de-escal techniqu
prevent inappropri shoot offic virtra multiscreen simul
decad librari experi partnership well renown trainer
save polic depart money term potenti litig reduc offic
health bill virtra offer custom grant option policegrantshelp
comprehens resourc grant assist includ search feder
state local corpor grant opportun hire grant writer get free help
virtra end net cash per share forecast per
share abl fulli fund organ growth
view
attract valuat vtsi stock current trade ep estim
price target base ep estim
multipl peer group compani provid product servic polic
militari price target also support dcf analysi rate take
account compani strong competit posit larg market opportun
posit view reflect compani conserv balanc sheet allow fund
growth organ track record profit
click full note
phase data chronic pancreat present
digest diseas week may
azurrx present previous announc posit phase data
chronic pancreat digest diseas week ddw
confer may san diego ca
phase data demonstr dose relat respons
sd posit safeti profil previous announc data
provid valid potenti treat exocrin
recal differenti consist
recombin lipas oppos standard care use porcine-
deriv lipas amylas proteas see could potenti
reduc pill burden per day per day similar
superior efficaci studi epi cystic fibrosi patient underway
conclus view present opportun azurrx
continu build awar therapeut potenti epi
phase option trial cystic fibrosi on-going top-line
data
present titl result multicent phase ii open-label non-
random studi spray dri recombin lipas treatment
exocrin pancreat insuffici patient chronic pancreat
present professor nam nguyen head educ research
intervent eu endoscopist royal adelaid hospit associ professor
univers adelaid
time pdt
locat room san diego convent center
phase trial open-label multicent dose escal studi
evalu safeti escal dose epi due chronic pancreat
primari endpoint safeti measur advers event clinic abnorm
day secondari endpoint includ efficaci measur coeffici
fat absorpt cfa chang baselin stool assess measur
bristol scale show favor safeti profil primari endpoint
good toler statist signific improv cfa
secondari endpoint observ highest dose cohort note
studi power efficaci howev data compar
seen treat chronic pancreat patient porcin agent
recombin yeast-deriv lipas amylas proteas
bodi suffici supplement enzym display acid-resist
properti allow greater enzymat activ relev acid condit
gut ph healthi patient ph patholog patient vitro test
shown effect ppe ph ph result
expect pill burden reduc pill per day ppe
pill per day pert make market us domin
porcine-deriv enzym ppe like nr creon pancrelipas
janssen nr licens pancreaz vivu vvu nr
space grow compound-annual-growth-rate still earli stage
may reduc pill burden reduc risk associ animal-deriv ppe improv
phase option trial epi cystic fibrosi cf on-going
enrol trial take place eu clinic site
sanction develop network support
cystic fibrosi foundat cff compani incorpor input fda
cf commun design trial trial open-label
crossov multicent head-to-head comparison standard
care soc pancreat enzym replac therapi pert adult cf patient
primari endpoint non-inferior coeffici fat absorpt cfa
week secondari endpoint includ stool weight sign malabsorpt
week top-line data expect read
click full note
updat saphyr revenu grow awar
build financ activ posit
bionano report revenu
respect repres y/i growth compani report
net loss year end period cash
balanc sheet
financ announc concurr earn releas debt/
equiti agreement consist term loan credit line atm
stock purchas agreement detail
net effect estim bionano cash
balanc sheet year oper capit could extend
depend revenu trajectori saphyr
view smart financ minim dilut
bionano manag continu execut growth strategi saphyr
includ sever recent announc upgrad improv
throughput reduc cost custom also see awar
build part increas number public see exampl note
conclus saphyr still earli stage growth perspect
expect revenu grow could lumpi saphyr continu gain
traction saphyr capabl map larg structur variat
reli sequenc could integr genom space alongsid
short-read nr long-read pacbio nr
acquir sequenc approach complet genom
interrog look bionano look much
quarter-to-quart revenu yet rather where/when awar
adopt may reach critic mass drive inflect
agreement yield total commit
atm w/ aspir capit initi purchas share
aggreg price remain atm sale share
base market price
debt facil innovatu east west bank three tranch
 expect drawn
term loan carri interest base sum greater
current bank prime rate ii addit
detail interest-onli period year follow repay period year
innovatu also receiv warrant coverag tranch bionano also
get revolv line credit
common stock purchas agreement affili innovatu
share aggreg
debt/equ bionano initi receiv million consist
drawn debt facil atm equiti purchas
use pay exist debt combin cash report
estim bionano current cash balanc sheet
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
receiv full disclosur compani maxim group coverag mention report pleas send
